tiprankstipranks
Trending News
More News >

Cidara Therapeutics Reports Positive Phase 2b Trial Results

Story Highlights
  • Cidara Therapeutics announced positive Phase 2b trial results for CD388 on June 23, 2025.
  • The trial showed significant efficacy and safety, potentially boosting Cidara’s market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cidara Therapeutics Reports Positive Phase 2b Trial Results

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Cidara Therapeutics ( (CDTX) ).

On June 23, 2025, Cidara Therapeutics announced positive results from its Phase 2b NAVIGATE trial for CD388, a drug aimed at preventing seasonal influenza. The trial demonstrated statistically significant prevention efficacy across all dose groups, with CD388 being well-tolerated and showing no unexpected adverse events. These results could enhance Cidara’s positioning in the antiviral market, and the company has submitted a meeting request to the FDA to discuss the Phase 3 trial design.

The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

Spark’s Take on CDTX Stock

According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.

Cidara Therapeutics is in a challenging position financially, with significant revenue declines and negative cash flows weighing heavily on its prospects. While technical indicators and valuation metrics paint a grim picture, the potential of CD388 and strategic corporate actions offer some hope for future recovery. Nevertheless, the current financial and operational challenges are substantial, resulting in a low overall stock score.

To see Spark’s full report on CDTX stock, click here.

More about Cidara Therapeutics

Cidara Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The company is particularly known for its work on antiviral and antifungal drugs, including its novel Drug-Fc-Conjugate (DFC) platform.

Average Trading Volume: 171,175

Technical Sentiment Signal: Hold

Current Market Cap: $272.6M

For a thorough assessment of CDTX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1